ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma
- PMID: 27823642
- DOI: 10.1016/j.critrevonc.2016.08.008
ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma
Abstract
ATM (ataxia telangiectasia mutated) is a DNA damage signaling-initiation kinase which has diverse function in responding to genotoxic stress to maintain its genomic integrity. Cells harboring loss-of-function ATM deficiencies demonstrate extreme radiosensitivity. The scope of radiotherapy has been considered very limited among patients with biallelic mutations or deletions of ATM due to its toxic effect on normal tissue. Mantle cell lymphoma (MCL) is a highly chemo-refractory tumor with generally poor outcome, especially if the patients develop resistance to frontline drugs. ATM is the most frequently mutated gene in MCL and recent experimental evidence demonstrated that this mutational status can be taken advantage of using radiotherapy. Radiotherapy should be considered in the treatment of mantle cell lymphoma with a curative intent.
Keywords: ASCT; ATM; MCL; Mutation; Personalized; Radio-sensitivity; Radiotherapy; TBI; Therapy.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2352-7. doi: 10.1073/pnas.0510441103. Epub 2006 Feb 3. Proc Natl Acad Sci U S A. 2006. PMID: 16461462 Free PMC article.
-
A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.Mol Cancer Res. 2015 Jan;13(1):120-9. doi: 10.1158/1541-7786.MCR-14-0240. Epub 2014 Sep 17. Mol Cancer Res. 2015. PMID: 25232030
-
Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma.Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5372-7. doi: 10.1073/pnas.0831102100. Epub 2003 Apr 15. Proc Natl Acad Sci U S A. 2003. PMID: 12697903 Free PMC article.
-
ATM mutations in sporadic lymphoid tumours.Leuk Lymphoma. 2002 Aug;43(8):1563-71. doi: 10.1080/1042819021000002884. Leuk Lymphoma. 2002. PMID: 12400598 Review.
-
Mantle cell lymphoma: a biological and therapeutic paradigm.Leuk Lymphoma. 2002 Apr;43(4):773-81. doi: 10.1080/10428190290016881. Leuk Lymphoma. 2002. PMID: 12153164 Review.
Cited by
-
Radiation induces NORAD expression to promote ESCC radiotherapy resistance via EEPD1/ATR/Chk1 signalling and by inhibiting pri-miR-199a1 processing and the exosomal transfer of miR-199a-5p.J Exp Clin Cancer Res. 2021 Sep 29;40(1):306. doi: 10.1186/s13046-021-02084-5. J Exp Clin Cancer Res. 2021. PMID: 34587992 Free PMC article.
-
Current overview and treatment of mantle cell lymphoma.F1000Res. 2018 Jul 25;7:F1000 Faculty Rev-1136. doi: 10.12688/f1000research.14122.1. eCollection 2018. F1000Res. 2018. PMID: 30109020 Free PMC article. Review.
-
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.PLoS One. 2022 Apr 29;17(4):e0267543. doi: 10.1371/journal.pone.0267543. eCollection 2022. PLoS One. 2022. PMID: 35486574 Free PMC article.
-
Prediction of Response to Radiotherapy by Characterizing the Transcriptomic Features in Clinical Tumor Samples across 15 Cancer Types.Comput Intell Neurosci. 2022 May 9;2022:5443709. doi: 10.1155/2022/5443709. eCollection 2022. Comput Intell Neurosci. 2022. PMID: 35586092 Free PMC article.
-
Management of Drug Resistance in Mantle Cell Lymphoma.Cancers (Basel). 2020 Jun 12;12(6):1565. doi: 10.3390/cancers12061565. Cancers (Basel). 2020. PMID: 32545704 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
